GlassScriptPhysician profile
Mehran R Moarefi
NPI 1780693572
$9,611.97
in general payments reported to CMS, 2019-2025
22 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $445 · 2021: $197 · 2022: $193 · 2023: $2,174 · 2024: $5,630 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Food and Beverage: $2,005 · Travel and Lodging: $17.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Food and Beverage | $2,004.77 |
| Travel and Lodging | $17.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,260.15 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $540.97 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.54 | 2019-2024 | Jardiance, Tradjenta |
| Novo Nordisk INC | $385.05 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $193.12 | 2023-2025 | |
| Amarin Pharma, INC. | $140.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $99.19 | 2019-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $83.33 | 2019-2020 | |
| Biogen, INC. | $68.54 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $66.53 | 2020-2021 | |
| Redhill Biopharma INC. | $39.38 | 2024 | Talicia |
| Kowa Pharmaceuticals America, INC. | $34.46 | 2025 | Zoryve |
| Astellas Pharma US INC | $33.26 | 2019-2020 | |
| Corcept Therapeutics | $31.92 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $31.62 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.64 | 2024 | |
| Boston Scientific Corporation | $28.44 | 2023 | Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $24.27 | 2019 | |
| Hologic Sales and Service, LLC | $23.07 | 2024 | Aptima, Thinprep 2000 Processor |
| Bioventus LLC | $20.57 | 2019 | |
| Shield Therapeutics INC | $14.60 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehran Moarefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.